S-1: NAYA Biosciences Seeks $10 Million in Unit Offering to Advance Oncology, Autoimmune, and Fertility Programs

NAYA Biosciences, formerly INVO Bioscience, is launching a unit offering to raise up to $10 million to fund its diverse portfolio of life science ventures.

Summary

• NAYA Biosciences, previously known as INVO Bioscience, is conducting a unit offering to raise up to $10 million.
• Each unit will consist of one share of common stock or one pre-funded warrant, and one warrant to purchase one share of common stock.
• The warrants are exercisable immediately and expire one year from issuance, at an exercise price equal to 100% of the unit offering price.
• Pre-funded warrants are offered to purchasers who would otherwise exceed beneficial ownership limits, with a purchase price of $0.01 less than the unit price and an exercise price of $0.01 per share.
• The offering has no minimum amount required to close and is expected to be completed within two business days of commencement.
• The company intends to use the proceeds for liabilities, clinical trials, product development, marketing, management, working capital, and potential acquisitions.
• NAYA Biosciences operates under a hub-and-spoke model, focusing on oncology, autoimmune diseases, and fertility.
• The company's therapeutic pipeline includes NY-303, a GPC-3 targeted NK engager for liver cancer, and NY-338, a CD38 targeted NK cell engager for multiple myeloma and autoimmune diseases.
• NAYA also has a fertility division, NAYA Womens Health, which includes INVO Centers and the INVOcell medical device.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has a diverse portfolio and promising technologies, it also faces significant financial challenges, regulatory hurdles, and competition. The lack of a minimum offering amount and the going concern warning are concerning.

Positives

• The unit offering provides a flexible way for NAYA Biosciences to raise capital.
• The company has a diverse portfolio spanning oncology, autoimmune diseases, and fertility.
• NAYA is utilizing a hub-and-spoke model which may allow for efficient resource allocation and strategic growth.
• The company has a clinical-stage pipeline with two bispecific antibodies, NY-303 and NY-338, addressing significant unmet medical needs.
• NAYA Womens Health has a revenue-generating fertility business with INVO Centers and the INVOcell device.

Negatives

• The offering has no minimum amount required to close, which may result in less capital raised than anticipated.
• The company has a history of net operating losses and needs additional capital to grow and finance its operations.
• The company is subject to risks associated with doing business globally and under various regulations.
• The company faces significant competition in the fertility and therapeutics industries.
• The company relies on third-party manufacturers and suppliers, which could disrupt its ability to import or export materials.

Risks

• The company's financial situation creates doubt about its ability to continue as a going concern.
• The company may not be able to successfully integrate Legacy NAYA and achieve the expected benefits.
• The company may not be able to successfully manage Wisconsin Fertility Institute and achieve the expected benefits.
• The company has a limited operating history and needs additional capital to grow and finance its operations.
• The company is subject to significant domestic and international governmental regulation.
• The company is subject to risks relating to federal and state healthcare fraud, waste, and abuse laws.
• The company may not be able to develop or continue its business if it fails to retain key personnel.
• The company is susceptible to cybersecurity breaches and cyber-related fraud.
• The company's fertility business is subject to significant competition.
• The FDA regulatory review process for medical devices is expensive, time-consuming and uncertain.
• The company's product candidates are in early stages of development and will require extensive additional preclinical and clinical testing.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company's product candidates may cause serious adverse events or undesirable side effects.
• The manufacturing of the company's product candidates will be very complex.
• The company is dependent on strategic partnerships and collaboration arrangements.
• The company is subject to risks in connection with changes in international, national, and local economic and market conditions.
• The company is subject to risks in connection with changes in international, national, and local economic and market conditions.
• The company is susceptible to cybersecurity breaches and cyber-related fraud.
• The company's products incorporate intellectual property rights that may be difficult to protect or may be found to infringe on the rights of others.
• The company is dependent on intellectual property licensed from third parties.
• Third-party claims of intellectual property infringement may prevent or delay the company's product discovery and development efforts.
• The company may not be able to protect its intellectual property rights throughout the world.
• The company may not identify or discover other product candidates and may fail to capitalize on programs or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.
• If product liability lawsuits are brought against the company, it may incur substantial liabilities and may be required to limit commercialization of its product candidates.
• The company's product candidates rely on the availability of specialty raw materials, which may not be available on acceptable terms or at all.
• If conflicts arise between the company and its collaborators or strategic partners, these parties may act in a manner adverse to the company and could limit its ability to implement its strategies.
• The company may seek to form collaborations in the future with respect to its product candidates, but may not be able to do so, which may cause the company to alter its development and commercialization plans.
• The company's business involves the use of hazardous materials which requires that the company, and its third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict or interrupt its business.
• The company has established a partnership with CytoLynx for the development and commercialization of its NY-303 bispecific antibody in greater China and there are substantial operational, financial, regulatory and political risks with this collaboration.
• The company's ability to develop proprietary technology platforms and products and its future growth depend on retaining NAYA Therapeutics key personnel and recruiting additional qualified personnel.
• The regulatory processes that will govern the approval of the company's product candidates are complex and changes in regulatory requirements could result in delays or discontinuation of development or unexpected costs in obtaining regulatory approval.
• The company is dependent on the successful clinical development, regulatory approval and subsequent commercialization of its product candidates.
• The company's fully integrated product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in or the company's inability to achieve regulatory approval, commercialization, or payor coverage of its product candidates.
• Even if any of the company's product candidates receive marketing approval, the company may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.
• Even if the company obtains and maintains approval for its product candidates from the FDA, it may never obtain approval outside the United States, which would limit its market opportunities.
• The company expects the product candidates it develops will be regulated as biologics, and therefore they may be subject to competition sooner than anticipated.
• The company's product candidates are in early stages of development, and therefore will require extensive additional preclinical and clinical testing.
• The company's approach to the development of product candidates based on its FLEX-NK cell engager antibody platform is unproven, and the company does not know whether it will be able to develop any products of commercial value, or if competing technological approaches will limit the commercial value of its product candidates or render its platforms obsolete.
• The company may not be able to file Investigational New Drug Applications to commence future clinical trials on the timelines it expects, and even if it is able to, the FDA or comparable foreign authority may not permit the company to proceed.
• The company's product candidates may cause serious adverse events or undesirable side effects or have other properties that may delay or prevent regulatory approval, cause the company to suspend or discontinue clinical trials, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
• Interim, top-line and preliminary data from the company's clinical trials that it announces or publishes from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
• The company faces significant competition from other biotechnology and pharmaceutical companies, which may result in others discovering, developing, or commercializing products before or more successfully than the company does.
• The company intends to study its product candidates in patient populations with significant comorbidities, and these patients may also receive treatment with cytotoxic lymphodepletion agents and other immunotherapies, and/or other treatments, and/or other treatments that may result in deaths or serious adverse or unacceptable side effects and require the company to abandon or limit its clinical development activities.
• The company may not identify or discover other product candidates and may fail to capitalize on programs or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.
• If product liability lawsuits are brought against the company, it may incur substantial liabilities and may be required to limit commercialization of its product candidates.
• The manufacturing of the company's product candidates will be very complex.
• The company depends on strategic partnerships and collaboration arrangements for the development of its FLEX-NK bispecific antibody platform.
• The company relies upon third parties to conduct certain research and development activities and assist the company with its preclinical trials and future clinical trials and commercial sale, if approved, of its product candidates.
• A disruption to the company's internal or third-party manufacturing operations, or its third-party suppliers or manufacturers inability to manufacture sufficient quantities of its antibody and cell product candidates at acceptable quality levels or costs, or at all, could materially and adversely affect the company's business.
• The company's product candidates rely on the availability of specialty raw materials, which may not be available to the company on acceptable terms or at all.
• If conflicts arise between the company and its collaborators or strategic partners, these parties may act in a manner adverse to the company and could limit its ability to implement its strategies.
• The company may seek to form collaborations in the future with respect to its product candidates, but may not be able to do so, which may cause the company to alter its development and commercialization plans.
• The company's business involves the use of hazardous materials which requires that the company, and its third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict or interrupt its business.
• The company has established a partnership with CytoLynx for the development and commercialization of its NY-303 bispecific antibody in greater China and there are substantial operational, financial, regulatory and political risks with this collaboration.
• The company's products incorporate intellectual property rights developed by the company that may be difficult to protect or may be found to infringe on the rights of others.
• The company depends on intellectual property licensed from third parties, and any failure to comply with the company's obligations under its license agreements or a termination of any of these license agreements could result in the loss of significant rights, which would harm the company's business.
• Third-party claims of intellectual property infringement may prevent or delay the company's product discovery and development efforts.
• The company may not be able to protect its intellectual property rights throughout the world.
• The company may not identify or discover other product candidates and may fail to capitalize on programs or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.
• If product liability lawsuits are brought against the company, it may incur substantial liabilities and may be required to limit commercialization of its product candidates.
• The company's insurance policies may also have various exclusions, and the company may be subject to a product liability claim for which it has no coverage.
• The company's inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products it develops, alone or with corporate collaborators.
• The company's product candidates rely on the availability of specialty raw materials, which may not be available to the company on acceptable terms or at all.
• If conflicts arise between the company and its collaborators or strategic partners, these parties may act in a manner adverse to the company and could limit its ability to implement its strategies.
• The company may seek to form collaborations in the future with respect to its product candidates, but may not be able to do so, which may cause the company to alter its development and commercialization plans.
• The company's business involves the use of hazardous materials which requires that the company, and its third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict or interrupt its business.
• The company has established a partnership with CytoLynx for the development and commercialization of its NY-303 bispecific antibody in greater China and there are substantial operational, financial, regulatory and political risks with this collaboration.

Future Outlook

The company believes its expanded corporate platform and strategy enhances its potential for value creation for shareholders through the combination of the existing revenue generating fertility business with the unique potential of innovative therapeutics. The company anticipates seeking initial regulatory approvals in the United States and the European Union, but may in the future submit applications for the regulatory approval of one or more of its product candidates to additional foreign regulatory authorities. The company expects that a substantial portion of its efforts and expenses over the next several years will be devoted to the development of its product candidates, including its lead product candidates, NY303 and NY-338, in its future clinical trials.

Management Comments

• The company believes its expanded corporate platform and strategy enhances its potential for value creation for shareholders through the combination of the existing revenue generating fertility business with the unique potential of innovative therapeutics.
• The company believes that it is uniquely positioned to capitalize on the growing demand for multifunctional antibodies, including immune cell engagers (T-Cell Engagers and NK-Cell Engagers) which bind simultaneously to the tumor cell and to immune cells redirecting immune cells to kill the tumor cells.

Industry Context

The document highlights the competitive landscape in the fertility and therapeutics industries, noting the presence of well-established companies and the development of new technologies. It also mentions the growing market for bispecific antibodies and the increasing demand for fertility treatments.

Comparison to Industry Standards

• The document mentions that the company's hub-and-spoke model is similar to that of Roivant, BridgeBio, and Puretech, which are significantly larger companies with more capital and resources.
• The document notes that the company's INVOcell device offers a more natural, safe, effective, and economical fertility treatment compared to conventional IVF.
• The document states that the company's NY-303 and NY-338 bispecific antibodies are first-in-class and address significant unmet medical needs.
• The document mentions that the company's NY-338 has shown a differentiated profile compared to daratumumab, a CD38-targeting monoclonal antibody.
• The document notes that the company's FLEX-NK cell engager antibody platform is a novel approach to immune-oncology.

Management Changes

Related Party Transactions

• The company issued a series of demand promissory notes in the aggregate principal amount of $550,000 to a related party, JAG, a company in which the company's Chief Financial Officer is a beneficiary.
• The company issued demand promissory notes in the aggregate principal amount of $220,000, of which $100,000 was received from its Chief Executive Officer and $100,000 was received from an entity controlled by its Chief Financial Officer.
• The company has entered into a number of joint ventures and partnerships for the operation of INVO Centers.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the unit offering and the potential for future capital raises.
• Employees may be impacted by changes in management and the company's financial stability.
• Customers of NAYA Womens Health may benefit from increased access to fertility treatments.
• Patients may benefit from the development of new therapies for cancer and autoimmune diseases.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company expects to complete the unit offering within two business days of commencement.
• The company intends to utilize the net proceeds of this offering for satisfaction of certain liabilities and contractual obligations, clinical trials, product development, marketing, strengthening the corporate management team, working capital and general corporate purposes.
• The company plans to initiate Phase I/IIa clinical trials for NY-303 and NY-338 in 2025.
• The company intends to build an early pipeline of best-in-class multifunctional antibodies for IND filing and Phase I/IIa clinical trial initiation in 2026.
• The company may use a portion of the proceeds for acquisitions of complementary businesses, technologies, or other assets.

Key Dates

Keywords

biotechnology, pharmaceutical, oncology, autoimmune, fertility, bispecific antibodies, NK cell engagers, clinical trials, medical devices, INVOcell, capital raise, drug development